A Study to Evaluate the Safety of Dabrafenib Alone or in Combination With Trametinib in Patients With Metastatic Melanoma

Trial Profile

A Study to Evaluate the Safety of Dabrafenib Alone or in Combination With Trametinib in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2016 New trial record
    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top